The relationship of 5-aminosalicylates’ use with the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD) has been the focus of a growing body of research.
Dr Bonovas and colleagues from Italy investigated this association through an updated meta-analysis of observational studies.
PubMed, Scopus and major conference proceedings were searched up to 2016.
The identified studies were evaluated for publication bias and heterogeneity.
The team incorporated 31 independent observational studies including 2137 cases of colorectal neoplasia.
Between-study heterogeneity was moderate, while strong suspicion of small-study effects was raised.
|5-aminosalicylates was protective against cancer, and dysplasia|
|Alimentary Pharmacology & Therapeutics|
The overall analysis revealed a protective association between 5-aminosalicylates’ use and colorectal neoplasia.
When the analysis was stratified according to study design and setting, the association was significant in cohort and case–control studies, population-based, and hospital-based studies.
The researchers found that exposure to 5-aminosalicylates was protective against cancer, and dysplasia.
The team noted that reduction in colorectal neoplasia risk was strong in ulcerative colitis, but nonsignificant in Crohn's disease.
The research team observed that mesalazine use was protective with evidence of a dose-effect.
The effect of sulfasalazine was marginally nonsignificant.
Dr Bonovas' team concludes, "Our findings support a potential chemopreventive role of 5-aminosalicylates in IBD."
"Further, high-quality prospective research is warranted."